Respironics ( RESP - NASDAQ ) has just reported the last Q results . Part of RESPIRONICS biz is actually the second leg in the DUOPOLY of RMD/RESP in the APNEA sleep disorder market . Key drivers for the Company's domestic revenue performance include a year-over-year increase of 15 percent in domestic sleep therapy products. Let's hope RMD did the same . First call consensus expected increase for RMD is 12% in EPS growth .It is expected to report EPS USc 28 for the Q and USD 1.06 for the FY , DuffShare
RMD - A possible profit clue
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.00 |
Change
-0.20(1.41%) |
Mkt cap $20.23B | |||
| Open | High | Low | Value | Volume |
| $14.02 | $14.06 | $13.94 | $25.71M | 1.839M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26000 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.01 | 7168 | 1 |
| Last update - 16.10pm 20/11/2018 (20 minute delay) ? |
 (live)
|
|||||
|
Last
$13.95 |
Change
-0.20 ( 1.76 %) |
||||
| Open | High | Low | Volume | ||
| $14.06 | $14.06 | $13.94 | 280186 | ||
| Last updated 15.59pm 20/11/2018 (live) ? | |||||
| RMD (ASX) Chart |